

MEDICAL PHARMACIES NEW DRUGS

Drug Information and News for Health Care Providers


October 2016

SIMBRINZA® (BRINZOLAMIDE/BRIMONIDINE TARTRATE OPHTHALMIC SUSPENSION)

Simbrinza® is a combination ophthalmic medication used for the treatment of glaucoma or ocular hypertension. It was recently approved on provincial formularies. Simbrinza® contains two medications that reduce intraocular pressure: brinzolamide, a carbonic anhydrase inhibitor, and brimonidine tartrate, an alpha-adrenergic agonist.



- **Dosage:** One drop in the affected eye(s) two times daily.
- **Uses:** To reduce intraocular pressure in:
 - o Residents with open-angle glaucoma
 - o Residents who have ocular hypertension and have not responded to treatment with a single medication product
- **Avoid** in residents who:
 - o Have severe kidney impairment
 - o Are on certain antidepressants (e.g., MAO Inhibitors, tricyclic antidepressants [TCAs])
 - o Have allergies to sulfonamides
- Single medication products that contain these ingredients include Azopt® (brinzolamide) and Alphagan® (brimonidine)



Please refer to the Simbrinza® product monograph for more comprehensive information regarding this medication.

References:

Simbrinza® Product Monograph. Alcon Canada Inc. December 2014.

Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. *The British Journal of Ophthalmology*. 2006;90(2):247-248. doi:10.1136/bjo.2005.075622.

Thomas R, Melton R. 2016 Clinical guide to ophthalmic drugs. Supplement to Review of Optometry. Available online at www.eyupdate.com. Accessed August 15, 2016.

RNAO. Nursing Best Practice Guidelines. Risk Assessment and Prevention of Pressure Ulcers. Revised 2011. Available online at http://rnao.ca/sites/rnao-ca/files/Risk_Assessment_and_Prevention_of_Pressure_Ulcers.pdf. Accessed August 22, 2016.